Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by scarlet1967on Mar 30, 2021 8:47am
97 Views
Post# 32904651

Over 50% of overweight people have NAFLD

Over 50% of overweight people have NAFLD

“Qiuwei Pan, PhD, of Erasmus University Medical Center, in Rotterdam, the Netherlands, and colleagues scanned the Medline, Cochrane, Web of Science, Embase and Google Scholar databases from their launch until November 2020. They aimed to establish the global prevalence of MAFLD among adults with obesity and overweight in the global general population.

 

The team short-listed 116 studies encompassing 2,667,052 participants with overweight or obesity. Irrespective of the diagnostic technique used, the global MAFLD prevalence was 51%. The rate was the same when looking at ultrasound diagnosis, the most common method. Across all studies, the pooled prevalence of type 2 diabetes was 20%, and the prevalence of metabolic syndrome was 58%.”

 

https://www.hepmag.com/article/fatty-liver-disease-global

<< Previous
Bullboard Posts
Next >>